Scarica l'app Stockscreener
19.27
0.77%
-0.15
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DYN Giù?
Forum
Previsione
Precedente Chiudi:
$19.42
Aprire:
$19.51
Volume 24 ore:
4.44M
Relative Volume:
1.52
Capitalizzazione di mercato:
$2.75B
Reddito:
-
Utile/perdita netta:
$-412.89M
Rapporto P/E:
-4.9922
EPS:
-3.86
Flusso di cassa netto:
$-361.93M
1 W Prestazione:
-4.98%
1M Prestazione:
+3.55%
6M Prestazione:
+33.26%
1 anno Prestazione:
-24.76%
Intervallo 1D:
$19.20
$19.96
Intervallo di 1 settimana:
$18.21
$23.96
Portata 52W:
$6.36
$26.69
Dyne Therapeutics Inc Stock (DYN) Company Profile
Nome
Dyne Therapeutics Inc
Settore
Industria
Telefono
(781) 786-8230
Indirizzo
1560 TRAPELO ROAD, WALTHAM
Confronta DYN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
19.27 | 2.77B | 0 | -412.89M | -361.93M | -3.86 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-10 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-10-10 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-25 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | Iniziato | Bernstein | Mkt Perform |
| 2025-06-11 | Ripresa | Raymond James | Outperform |
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-05-29 | Iniziato | Evercore ISI | Outperform |
| 2025-03-12 | Iniziato | BMO Capital Markets | Outperform |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-13 | Iniziato | Robert W. Baird | Outperform |
| 2024-11-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-10-24 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-05-21 | Reiterato | Chardan Capital Markets | Buy |
| 2024-04-30 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-20 | Iniziato | H.C. Wainwright | Buy |
| 2023-02-27 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | Iniziato | Oppenheimer | Outperform |
| 2023-01-26 | Iniziato | Guggenheim | Buy |
| 2022-07-20 | Iniziato | Chardan Capital Markets | Buy |
| 2022-07-12 | Iniziato | Raymond James | Outperform |
| 2020-10-12 | Iniziato | JP Morgan | Overweight |
| 2020-10-12 | Iniziato | Jefferies | Buy |
| 2020-10-12 | Iniziato | Piper Sandler | Overweight |
| 2020-10-12 | Iniziato | Stifel | Buy |
Mostra tutto
Dyne Therapeutics Inc Borsa (DYN) Ultime notizie
Frazier Life Sciences Management L.P. Has $14.34 Million Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
TFG Asset Management GP Ltd Acquires New Stake in Dyne Therapeutics, Inc. $DYN - MarketBeat
Braidwell LP Has $31.16 Million Stock Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity - MSN
WilmerHale Advises Dyne Therapeutics on its $402.5 Million Public Offering of Common Stock - WilmerHale
Why Dyne Therapeutics stock was a big winner on Wednesday - MSN
Stifel Nicolaus Reaffirms Their Buy Rating on Dyne Therapeutics (DYN) - theglobeandmail.com
HighVista Strategies LLC Sells 52,096 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Stifel Maintains Dyne Therapeutics (DYN) Buy Recommendation - Nasdaq
Dyne Therapeutics raises $402.5 million in upsized public offering By Investing.com - Investing.com Nigeria
Dyne Therapeutics raises $402.5 million in upsized public offering - Investing.com
Dyne Therapeutics prices $350 stock offering - MSN
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares - The Manila Times
Dyne Therapeutics Closes $402.5 Million Upsized Public Offering of Common Stock - Quiver Quantitative
Dyne Therapeutics (NASDAQ:DYN) Price Target Raised to $39.00 at Stifel Nicolaus - MarketBeat
Dyne, citing positive trial data, to ask FDA to approve DMD therapy - Muscular Dystrophy News
Stifel Raises Price Target for Dyne Therapeutics (DYN) to $39.00 - GuruFocus
Dyne Therapeutics Shares Rise After Announcing Positive Topline Results for z-rostudirsen in Phase 1/2 DMD Trial - Insider Monkey
Dyne Therapeutics (DYN) Upgraded by Oppenheimer, Potential 50% U - GuruFocus
Why Dyne Therapeutics Stock Was a Big Winner on Wednesday - Finviz
Oppenheimer Upgrades Dyne Therapeutics (DYN) - Nasdaq
Dyne Therapeutics Announces Upsized Public Offering - TipRanks
Dyne Therapeutics (DYN) Upgraded by Oppenheimer, Potential 50% Upside - GuruFocus
Dyne stock upgraded at Oppenheimer (DYN:NASDAQ) - Seeking Alpha
11 High Short Interest Stocks to Buy Right Now - Insider Monkey
Dyne Therapeutics (NASDAQ:DYN) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Dyne Therapeutics' Biggest Catalyst is Avidity Biosciences' DM1 Readout in H2 2026, Oppenheimer Says - marketscreener.com
Dyne Therapeutics: Why The $350M Public Offering Was Critical (NASDAQ:DYN) - Seeking Alpha
Dyne Therapeutics Surges Amid Positive Trial Results and Financial Adjustments - timothysykes.com
Oppenheimer Upgrades Dyne Therapeutics (DYN) to Outperform, Rais - GuruFocus
Oppenheimer Upgrades Dyne Therapeutics to Outperform From Perform, Adjusts PT to $40 From $11 - marketscreener.com
Dyne Therapeutics (DYN) Sees Upgrade and Potential Stock Upside - GuruFocus
HC Wainwright Has Positive Outlook for DYN FY2027 Earnings - MarketBeat
Dyne Therapeutics Prices $350 Million Public Offering - marketscreener.com
Dyne Therapeutics Prices Upsized Public Offering Of 18.98 Mln Shares - Nasdaq
Dyne Therapeutics prices upsized public offering at $18.44 per share - Investing.com
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock - The Manila Times
Dyne Therapeutics Announces Pricing of Upsized Public Offering of Common Stock Amounting to $350 Million - Quiver Quantitative
Dyne Therapeutics says co prices public offering at $18.44 per share - marketscreener.com
Dyne Therapeutics Says Co Prices Public Offering At $18.44 Per Share - TradingView — Track All Markets
Why Dyne Therapeutics Stock Tanked on Tuesday - The Globe and Mail
Dyne Therapeutics (DYN) Navigates a Paradoxical Day: Positive Clinical Data Overshadowed by Dilution Fears - Markets Financial Content
Biggest Market Movers Today, Dec. 9: WRBY, DYN, & More - The Motley Fool
Dyne Therapeutics stock tumbles on $300 million share offering By Investing.com - Investing.com Canada
Dyne Therapeutics stock tumbles on $300 million share offering - Investing.com
Dyne Therapeutics (DYN) Climbs 9.5% on Stellar Results for DMD Therapy Candidate - Finviz
Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets - AOL.com
Dyne to seek accelerated approval of DMD drug on Phase I/II data - Yahoo Finance
Dyne Therapeutics (NASDAQ:DYN) Shares Gap DownHere's What Happened - MarketBeat
Dyne Therapeutics (DYN) Target Price Raised to $50 by Morgan Sta - GuruFocus
Dyne Therapeutics (DYN) Stock Sees Significant Drop - GuruFocus
Dyne Therapeutics Inc Azioni (DYN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):